X4 Pharmaceuticals Inc expected to post a loss of $4.34 a share - Earnings Preview

X4 Pharmaceuticals

04/08/2025 14:14

X4 Pharmaceuticals Inc XFOR.OQ XFOR.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

The Boston Massachusetts-based  company is expected to report a 186.3% increase in revenue to $1.612 million from $563 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for X4 Pharmaceuticals Inc is for a loss of $4.34 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $14.00, about 88.6% above its last closing price of $1.60

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-5.38
-4.44
0.04
Beat
100.9
Dec. 31 2025
-5.40
-5.25
-6.00
Missed
-14.3
Sep. 30 2024
-4.50
-5.19
-5.40
Missed
-4.1​
Jun. 30 2024
3.80
0.17
-2.10
Missed
-1,325.9
​​Mar. 31 2024
-4.65
-4.89
-7.80
Missed
-59.6
Dec. 31 2023
-5.10
-4.59
-3.00
Beat
34.6​
Sep. 30 2023
-4.61
-4.47
-0.30
Beat
93.3
Jun. 30 2023
-4.86
-4.90
-9.90
Missed
-102

This summary was machine generated August 4 at 13:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)